Skip to main content
MNPR
NASDAQ Life Sciences

Monopar Kicks Off Rolling NDA for ALXN1840 in Wilson Disease

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$113.57
Mkt Cap
$760.812M
52W Low
$29.18
52W High
$115
52W Position info
289% above low
Off High info
1.2% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

MNPR has more than doubled off its 52-week low of $29.18.

Summary

Monopar has launched the rolling NDA submission for ALXN1840 in Wilson disease, a pivotal regulatory move that could yield the first new therapy for the condition in decades and a potential Priority Review Voucher.


Key Events · Product Development and Regulatory · MNPR

  • Rolling NDA Submission Initiated

    Under an FDA-authorized rolling review, Monopar has submitted the first completed sections of the NDA for ALXN1840 in Wilson disease.

  • Regulatory Designations Support Approval

    ALXN1840 carries Fast Track, Orphan Drug, and Rare Pediatric Disease designations—the latter offering a potential Priority Review Voucher upon approval.

  • First-in-Class Potential

    If approved, ALXN1840 would be the first therapy with a novel mechanism of action for Wilson disease in decades, addressing a significant unmet need.

  • Timeline on Track

    The initiation aligns with the company's previously stated mid-2026 NDA submission target, demonstrating solid execution on its regulatory strategy.


Analysis · MNPR · Life Sciences

A critical regulatory step is underway: Monopar has begun the rolling NDA submission for ALXN1840, its first-in-class Wilson disease therapy. The FDA's green light for a rolling review means completed sections can be evaluated now, potentially shortening the path to approval. With Fast Track, Orphan Drug, and Rare Pediatric Disease designations already in hand, a successful NDA could deliver the first novel treatment for Wilson disease in decades—and a valuable Priority Review Voucher. Trading near its 52-week high, the stock reflects elevated expectations, and this milestone confirms the company is on track with its mid-2026 submission target.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MNPR was trading at $113.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $760.8M. The 52-week trading range was $29.18 to $115.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MNPR - Latest Insights

MNPR
Nov 12, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $70.30
Real-time Price: $70.70 info
Change: +$0.400 (+0.57%) info
Market Cap: $481.557M info
MNPR
Nov 12, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $70.30
Real-time Price: $70.70 info
Change: +$0.400 (+0.57%) info
Market Cap: $481.557M info
MNPR
Aug 12, 2026, 9:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $115.19
Real-time Price: $70.70 info
Change: -$44.49 (-39%) info
Market Cap: $481.557M info
MNPR
Aug 12, 2026, 9:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $114.46
Real-time Price: $70.70 info
Change: -$43.76 (-38%) info
Market Cap: $481.557M info
MNPR
Aug 12, 2026, 9:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $115.19
Real-time Price: $70.70 info
Change: -$44.49 (-39%) info
Market Cap: $481.557M info